SILVER SPRING
Dupixent cleared for pediatric chronic spontaneous urticaria
- Sponsor
- Sanofi and Regeneron
- Drug
- Dupixent · dupilumab
- Indication
- chronic spontaneous urticaria in children
FDA approved Dupixent (dupilumab) for children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment.
What this means
Dupixent is an injectable antibody drug that blocks two proteins involved in allergic inflammation, helping control symptoms like hives and itching. Today FDA approved Dupixent for children aged two to 11 with chronic spontaneous urticaria who still have symptoms after taking antihistamines. This decision could provide younger patients with a new treatment option for persistent hives that don’t respond to standard therapies.